Ingo Kleiter

14.0k total citations · 3 hit papers
121 papers, 5.0k citations indexed

About

Ingo Kleiter is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, Ingo Kleiter has authored 121 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Pathology and Forensic Medicine, 43 papers in Neurology and 31 papers in Oncology. Recurrent topics in Ingo Kleiter's work include Multiple Sclerosis Research Studies (78 papers), Peripheral Neuropathies and Disorders (40 papers) and Polyomavirus and related diseases (17 papers). Ingo Kleiter is often cited by papers focused on Multiple Sclerosis Research Studies (78 papers), Peripheral Neuropathies and Disorders (40 papers) and Polyomavirus and related diseases (17 papers). Ingo Kleiter collaborates with scholars based in Germany, United States and United Kingdom. Ingo Kleiter's co-authors include Friedemann Paul, Ralf Gold, Sven Jarius, Orhan Aktaş, Brigitte Wildemann, Jacqueline Palace, J. de Sèze, Tania Kümpfel, Kazuo Fujihara and Takashi Yamamura and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Ingo Kleiter

115 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing

2018 502 citations Sven Jarius, Friedemann Paul et al. Journal of Neuroinflammation profile →
Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)

2013 417 citations Corinna Trebst, Sven Jarius et al. profile →
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

2019 415 citations Takashi Yamamura, Ingo Kleiter et al. profile →

Peers

Countries citing papers authored by Ingo Kleiter

Since Specialization

Citations

This map shows the geographic impact of Ingo Kleiter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingo Kleiter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingo Kleiter more than expected).

Fields of papers citing papers by Ingo Kleiter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingo Kleiter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingo Kleiter. The network helps show where Ingo Kleiter may publish in the future.

Co-authorship network of co-authors of Ingo Kleiter

This figure shows the co-authorship network connecting the top 25 collaborators of Ingo Kleiter. A scholar is included among the top collaborators of Ingo Kleiter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingo Kleiter. Ingo Kleiter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study 2025 ·Neurology Neuroimmunology & Neuroinflammation ·Jeffrey L. Bennett, Kazuo Fujihara, Albert Saiz, Anthony Traboulsee, Benjamin Greenberg, Brian G. Weinshenker, Francesco Patti, Ingo Kleiter, Jacqueline Palace, J. de Sèze, Rachael A Evans, Kathleen Blondeau, Gaëlle Klingelschmitt, (unknown), (unknown), Takashi Yamamura	1
2	Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study 2025 ·Neurology Neuroimmunology & Neuroinflammation ·Jeffrey L. Bennett, Kazuo Fujihara, Albert Saiz, Anthony Traboulsee, Benjamin Greenberg, Brian G. Weinshenker, Francesco Patti, Ingo Kleiter, Jacqueline Palace, J. de Sèze, Rachael A Evans, Kathleen Blondeau, Gaëlle Klingelschmitt, (unknown), (unknown), Takashi Yamamura	1
3	Cognitive Impairment, Associated Clinical Factors, and MR Volumetric Measures in Myelin Oligodendrocyte Glycoprotein-IgG–Associated Disease 2024 ·Neurology Neuroimmunology & Neuroinflammation ·(unknown), (unknown), Carolin Schwake, Ingo Kleiter, Bianca Teegen, (unknown), Christian Prehn, (unknown), Marius Ringelstein, Orhan Aktaş, Refik Pul, (unknown), Carsten Lukas, Iris‐Katharina Penner, Ralf Gold, Ruth Schneider, (unknown)	2
4	Progressive Retinal and Optic Nerve Damage in a Mouse Model of Spontaneous Opticospinal Encephalomyelitis 2022 ·Frontiers in Immunology ·(unknown), Sabrina Reinehr, Steffen Haupeltshofer, (unknown), (unknown), Ingo Kleiter, H. Burkhard Dick, Ralf Gold, Simon Faissner, Stephanie C. Joachim	7
5	Impact of a multimedia website with patient experiences of multiple sclerosis (PExMS) on immunotherapy decision-making: study protocol for a pilot randomised controlled trial in a mixed-methods design 2021 ·Pilot and Feasibility Studies ·(unknown), Karin Riemann-Lorenz, Christopher Kofahl, Jutta Scheiderbauer, (unknown), Ingo Kleiter, Jürgen Kasper, Sascha Köpke, Susanne Lezius, Antonia Zapf, Anne Christin Rahn, Christoph Heesen	6
6	Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study 2020 ·Contemporary Clinical Trials Communications ·Ahmed Abdelhak, André Huss, Alexander Stahmann, Makbule Şenel, Markus Krumbholz, Markus C. Kowarik, Joachim Havla, Tania Kümpfel, Ingo Kleiter, (unknown), Uwe K. Zettl, (unknown), (unknown), Tim Friede, Albert C. Ludolph, Ulf Ziemann, Hayrettin Tumani	5
7	Efficacy of Satralizumab (SA237) in Subgroups of Patients in SakuraSky: A Phase III Double-Blind, Placebo-Controlled, Add-On Study in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) 2020 ·Multiple Sclerosis Journal ·Tomohiko Yamamura, Ingo Kleiter, (unknown), Jacqueline Palace, Benjamin Greenberg, Beata Zakrzewska‐Pniewska, F. Patti, (unknown), Albert Saiz, Masayuki Haramura, Yukihiro Terada, Yuichi Kawata, J. de Sèze	1
8	SMAD signaling promotes melanoma metastasis independently of phenotype switching 2019 ·Journal of Clinical Investigation ·Eylül Tuncer, (unknown), Daniel Zingg, Sandra Varum, Phil F. Cheng, Sandra N. Freiberger, Chu‐Xia Deng, Ingo Kleiter, Mitchell P. Levesque, Reinhard Dummer, Lukas Sommer	37
9	A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica spectrum disorder (NMOSD) 2018 ·Multiple Sclerosis Journal ·J. de Sèze, Ingo Kleiter, (unknown), Jacqueline Palace, Benjamin Greenberg, Beata Zakrzewska‐Pniewska, Francesco Patti, (unknown), Ana Sáiz, Yukihiro Terada, Yuichi Kawata, Pádraig Wright, (unknown)	5
10	MOG encephalomyelitis: international recommendations on diagnosis and antibody testing breakdown → 2018 ·Journal of Neuroinflammation ·Sven Jarius, Friedemann Paul, Orhan Aktaş, Nasrin Asgari, Russell C. Dale, J. de Sèze, Diego Franciotta, Kazuo Fujihara, A. Jacob, Ho Jin Kim, Ingo Kleiter, Tania Kümpfel, Michael Levy, Jacqueline Palace, Klemens Ruprecht, Albert Saiz, Corinna Trebst, Brian G. Weinshenker, Brigitte Wildemann	502
11	A double-blind placebo-controlled study of satralizumab (SA237), a recycling anti-IL-6 receptor monoclonal antibody, as add-on therapy for neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD) 2018 ·European Journal of Neurology ·(unknown), Ingo Kleiter, (unknown), Jacqueline Palace, Benjamin Greenberg, Beata Zakrzewska‐Pniewska, Francesco Patti, (unknown), Ana Sáiz, Yukihiro Terada, Yuichi Kawata, Pádraig Wright, J. de Sèze	1
12	Management of Immune-Mediated Paraneoplastic Neurological Disorders 2017 ·Ilya Ayzenberg, Ralf Gold, Ingo Kleiter	1
13	Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study 2017 ·BMC Neurology ·Ingo Kleiter, Michael Lang, (unknown), Christiane Norenberg, (unknown), Markus Schürks	15
14	Frühzeitiges Auftreten eines Fingolimod-assoziierten Makulaödems 2017 ·Der Ophthalmologe ·(unknown), Ingo Kleiter, (unknown), (unknown), (unknown), H. Burkhard Dick, Vinodh Kakkassery	2
15	Relevance of endoglin, IL-1α, IL-1β and anti-ovarian antibodies in females with multiple sclerosis 2016 ·Journal of the Neurological Sciences ·Jan Thöne, Ingo Kleiter, Anna Stahl‐Pehe, Gisa Ellrichmann, Ralf Gold, Kerstin Hellwig	7
16	Demographic and clinical features of neuromyelitis optica: A review 2015 ·Multiple Sclerosis Journal ·Lekha Pandit, Nasrin Asgari, Metha Apiwattanakul, Jacqueline Palace, Friedemann Paul, MI Leite, Ingo Kleiter, Tanuja Chitnis	249
17	Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial 2013 ·Journal of Neurology Neurosurgery & Psychiatry ·Sascha Köpke, Simone Kern, Tjalf Ziemssen, Martin Berghoff, Ingo Kleiter, Martin Marziniak, Friedemann Paul, Eik Vettorazzi, Jana Pöttgen, (unknown), Jürgen Kasper, Christoph Heesen	63
18	Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy 2013 ·JAMA Neurology ·Ilya Ayzenberg, Ingo Kleiter, Alexandra Schröder, Kerstin Hellwig, Andrew Chan, Takashi Yamamura, Ralf Gold	167
19	Intraventricular cytarabine in a case of idiopathic hypertrophic pachymeningitis 2004 ·Journal of Neurology Neurosurgery & Psychiatry ·Ingo Kleiter	19
20	Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade glioma 2004 ·Cancer ·Peter Hau, Klaus Fabel, (unknown), Petra Rümmele, Oliver Grauer, Annekatrin Bock, (unknown), Wolfgang Dietmaier, Jörg Dietrich, (unknown), (unknown), (unknown), (unknown), Ingo Kleiter, (unknown), (unknown), Alexander Brawanski, Andreas Steinbrecher, Jörg Marienhagen, Ulrich Bogdahn	161

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact